Verily Life Sciences, a subsidiary of Alphabet, has announced a collaboration with Samsung Electronics America aimed at advancing clinical research by combining wearable device data with Verily’s health analytics platform. The partnership will integrate sensor data from the Samsung Galaxy Watch 8 into Verily’s precision health platform, Pre, creating a system designed to support real-world research and population health monitoring.
Through the integration, data collected from the Galaxy Watch will be incorporated into Verily’s AI-native platform and made available within its Viewpoint Evidence solution. This will allow research sponsors to conduct studies using real-world datasets and maintain access to participant cohorts that can be contacted again for follow-up research.
The collaboration combines Verily’s large dataset of consented research participants with multiple sources of health information, including wearable sensor data, medical records, survey responses and additional third-party data. By bringing these sources together at the individual level, the platform aims to provide researchers with deeper insights into patient health and behavior.
Sponsors will also be able to design and run studies using Verily’s registry population while analysing long-term data related to sleep patterns, physical activity and other health outcomes. Verily will recruit and engage Samsung device users for participation in research studies, which the companies say should help maintain consistent device usage and improve the quality and continuity of collected data.
The collaboration relies on several components of Verily’s research infrastructure. The Pre platform is designed to allow researchers to exchange, govern and analyse biomedical data while building and deploying AI models within research and clinical workflows. Supporting tools include Refinery, which harmonizes complex datasets such as clinical notes and multi-omics information into structured, research-ready assets, and Workbench, a cloud-based environment built to support secure data analytics, governance and the development lifecycle of AI and machine learning models.
In addition to providing the platform infrastructure, Verily will contribute expertise in AI-driven analytics, digital measurement and clinical trial support, including regulatory, operational and compliance capabilities. The companies also said they will explore the joint development of new end-to-end solutions aimed at improving how clinical research is conducted and how real-world health data is collected and analysed.
Click here to read the original news story.